Startseite Economic evaluation of procalcitonin-guided antibiotic therapy in acute respiratory infections: a Chinese hospital system perspective
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Economic evaluation of procalcitonin-guided antibiotic therapy in acute respiratory infections: a Chinese hospital system perspective

  • Ivana Stojanovic EMAIL logo , John E. Schneider , Long Wei , Zhan Hong , Clara Keane und Philipp Schuetz
Veröffentlicht/Copyright: 22. September 2016
Veröffentlichen auch Sie bei De Gruyter Brill
Manuskript einreichen Informationen für Autor*innen
Clinical Chemistry and Laboratory Medicine (CCLM)
Aus der Zeitschrift Clinical Chemistry and Laboratory Medicine (CCLM) Band 55 Heft 4

Abstract

Background:

Cost-impact models have indicated that in the USA, the use of antibiotic stewardship protocols based on procalcitonin (PCT) levels for patients with suspected acute respiratory tract infection results in cost savings. Our objective was to assess the cost impact of adopting PCT testing among patients with acute respiratory infections (ARI) from the perspective of a typical hospital system in urban China.

Methods:

To conduct an economic evaluation of PCT testing versus usual care we built a cost-impact model based on a previously published patient-level meta-analysis data of randomized trials including Chinese sites. The data were adapted to the China setting by applying the results to mean lengths of stay, costs, and practice patterns typically found in China. We estimated the annual ARI visit rate for the typical hospital system (assumed to be 1650 beds) and ARI diagnosis.

Results:

In the inpatient setting, the costs of PCT-guided care compared to usual care for a cohort of 16,405 confirmed ARI patients was almost 1.1 million Chinese yuan (CNY), compared to almost 1.8 million CNY for usual care, resulting in net savings of 721,563 CNY to a typical urban Chinese hospital system for 2015. In the ICU and outpatient settings, savings were 250,699 CNY and 2.4 million CNY, respectively. The overall annual net savings of PCT-guided care was nearly 3.4 million CNY.

Conclusions:

Substantial savings are associated with PCT protocols of ARI across common China hospital treatment settings mainly by direct reduction in unnecessary antibiotic utilization.

Keywords: antibiotic stewardship; Chinese health system; cost saving; economic evaluation; procalcitonin; respiratory infection
Corresponding author: Ivana Stojanovic, MA, Health Economist, Avalon Health Economics, 26 Washington Street, 3rd Floor, Morristown, NJ 07960, USA, Phone: +1.862.260.9194 (Office); +1.646.725.4100 (Cell)

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: Support for this project was provided by Medical Affairs at BioMerieux.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Wong WB, Carlson JJ, Thariani R, Veenstra DL. Cost effectiveness of pharmacogenomics: a critical and systematic review. Pharmacoeconomics 2010;28:1001–13.10.2165/11537410-000000000-00000Suche in Google Scholar PubMed

2. Assasi N, Schwartz L, Tarride JE, Goeree R, Xie F. Economic evaluations conducted for assessment of genetic testing technologies: a systematic review. Genet Test Mol Biomarkers 2012;16:1322–35.10.1089/gtmb.2012.0178Suche in Google Scholar PubMed

3. Beaulieu M, de Denus S, Lachaine J. Systematic review of pharmacoeconomic studies of pharmacogenomic tests. Pharmacogenomics 2010;11:1573–90.10.2217/pgs.10.145Suche in Google Scholar PubMed

4. Chowdhury P, Kehl D, Choudhary R, Maisel A. The use of biomarkers in the patient with heart failure. Curr Cardiol Rep 2013;15:372.10.1007/s11886-013-0372-4Suche in Google Scholar PubMed

5. Diop D. Maximizing the quality and cost-effectiveness of cardiac care with laboratory technology and process improvements. J Cardiovasc Manag 2003;14:19–23.Suche in Google Scholar

6. Schuetz P, Amin DN, Greenwald JL. Role of procalcitonin in managing adult patients with respiratory tract infections. Chest 2012;141:1063–73.10.1378/chest.11-2430Suche in Google Scholar PubMed

7. Shen B, Hwang J. The clinical utility of precision medicine: properly assessing the value of emerging diagnostic tests. Clin Pharmacol Ther 2010;88:754–6.10.1038/clpt.2010.236Suche in Google Scholar PubMed

8. Wong W. A health plan’s integration of molecular diagnostics and the impact on treatment pathways for quality care. Manag Care 2008;17(7 Suppl 7):13–6; discussion 7–8.Suche in Google Scholar

9. Barbier F, Andremont A, Wolff M, Bouadma L. Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management. Curr Opin Pulm Med 2013;19:216–28.10.1097/MCP.0b013e32835f27beSuche in Google Scholar PubMed

10. Christ-Crain M, Muller B. Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J 2007;30:556–73.10.1183/09031936.00166106Suche in Google Scholar PubMed

11. Christ-Crain M, Opal SM. Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumonia. Crit Care 2010;14:203.10.1186/cc8155Suche in Google Scholar PubMed PubMed Central

12. Faix JD. Biomarkers of sepsis. Crit Rev Clin Lab Sci 2013;50: 23–36.10.3109/10408363.2013.764490Suche in Google Scholar PubMed PubMed Central

13. File TM, Jr. New diagnostic tests for pneumonia: what is their role in clinical practice? Clin Chest Med 2011;32:417–30.10.1016/j.ccm.2011.05.011Suche in Google Scholar PubMed PubMed Central

14. Gerber JS, Prasad PA, Fiks AG, Localio AR, Grundmeier RW, Bell LM, et al. Effect of an outpatient antimicrobial stewardship intervention on broad-spectrum antibiotic prescribing by primary care pediatricians: a randomized trial. J Am Med Assoc 2013;309:2345–52.10.1001/jama.2013.6287Suche in Google Scholar PubMed

15. Gjelstad S, Hoye S, Straand J, Brekke M, Dalen I, Lindbaek M. Improving antibiotic prescribing in acute respiratory tract infections: cluster randomised trial from Norwegian general practice (prescription peer academic detailing (Rx-PAD) study). Br Med J 2013;347:f4403.10.1136/bmj.f4403Suche in Google Scholar PubMed PubMed Central

16. Lippi G, Meschi T, Cervellin G. Inflammatory biomarkers for the diagnosis, monitoring and follow-up of community-acquired pneumonia: clinical evidence and perspectives. Eur J Intern Med 2011;22:460–5.10.1016/j.ejim.2011.02.023Suche in Google Scholar PubMed

17. Luyt CE, Combes A, Trouillet JL, Chastre J. Biomarkers to optimize antibiotic therapy for pneumonia due to multidrug-resistant pathogens. Clin Chest Med 2011;32:431–8.10.1016/j.ccm.2011.05.004Suche in Google Scholar PubMed

18. Mira JP, Max A, Burgel PR. The role of biomarkers in community-acquired pneumonia: predicting mortality and response to adjunctive therapy. Crit Care 2008;12(Suppl 6):S5.10.1186/cc7028Suche in Google Scholar PubMed PubMed Central

19. Mitsuma SF, Mansour MK, Dekker JP, Kim J, Rahman MZ, Tweed-Kent A, et al. Promising new assays and technologies for the diagnosis and management of infectious diseases. Clin Infect Dis 2013;56:996–1002.10.1093/cid/cis1014Suche in Google Scholar PubMed PubMed Central

20. O’Brien DJ, Gould IM. Maximizing the impact of antimicrobial stewardship: the role of diagnostics, national and international efforts. Curr Opin Infect Dis 2013;26:352–8.10.1097/QCO.0b013e3283631046Suche in Google Scholar PubMed

21. Reinhart K, Hartog CS. Biomarkers as a guide for antimicrobial therapy. Int J Antimicrob Agents 2010;36(Suppl 2):S17–21.10.1016/j.ijantimicag.2010.11.009Suche in Google Scholar PubMed

22. Schuetz P, Christ-Crain M, Muller B. Biomarkers to improve diagnostic and prognostic accuracy in systemic infections. Curr Opin Crit Care 2007;13:578–85.10.1097/MCC.0b013e3282c9ac2aSuche in Google Scholar PubMed

23. Schuetz P, Haubitz S, Mueller B. Do sepsis biomarkers in the emergency room allow transition from bundled sepsis care to personalized patient care? Curr Opin Crit care 2012;18:341–9.10.1097/MCC.0b013e328354b2c8Suche in Google Scholar

24. Schuetz P, Litke A, Albrich WC, Mueller B. Blood biomarkers for personalized treatment and patient management decisions in community-acquired pneumonia. Curr Opin Infect Dis 2013;26:159–67.10.1097/QCO.0b013e32835d0becSuche in Google Scholar

25. Seligman R, Ramos-Lima LF, Oliveira Vdo A, Sanvicente C, Pacheco EF, Dalla Rosa K. Biomarkers in community-acquired pneumonia: a state-of-the-art review. Clinics (Sao Paulo) 2012;67:1321–5.10.6061/clinics/2012(11)17Suche in Google Scholar

26. Upadhyay S, Niederman MS. Biomarkers: what is their benefit in the identification of infection, severity assessment, and management of community-acquired pneumonia? Infect Dis Clin North Am 2013;27:19–31.10.1016/j.idc.2012.11.003Suche in Google Scholar PubMed

27. Ventetuolo CE, Levy MM. Biomarkers: diagnosis and risk assessment in sepsis. Clin Chest Med 2008;29:591–603, vii.10.1016/j.ccm.2008.07.001Suche in Google Scholar PubMed

28. Vincent JL, Beumier M. Diagnostic and prognostic markers in sepsis. Expert Rev Anti Infect Ther 2013;11:265–75.10.1586/eri.13.9Suche in Google Scholar PubMed

29. Aabenhus R, Jensen JU. Procalcitonin-guided antibiotic treatment of respiratory tract infections in a primary care setting: are we there yet? Prim Care Respir J 2011;20:360–7.10.4104/pcrj.2011.00064Suche in Google Scholar PubMed PubMed Central

30. Fazili T, Endy T, Javaid W, Maskey M. Role of procalcitonin in guiding antibiotic therapy. Am J Health Syst Pharm 2012;69:2057–61.10.2146/ajhp110736Suche in Google Scholar PubMed

31. Foushee JA, Hope NH, Grace EE. Applying biomarkers to clinical practice: a guide for utilizing procalcitonin assays. J Antimicrob Chemother 2012;67:2560–9.10.1093/jac/dks265Suche in Google Scholar PubMed

32. Riedel S. Procalcitonin and the role of biomarkers in the diagnosis and management of sepsis. Diagn Microbiol Infect Dis 2012;73:221–7.10.1016/j.diagmicrobio.2012.05.002Suche in Google Scholar PubMed

33. Schuetz P, Briel M, Christ-Crain M, Stolz D, Bouadma L, Wolff M, et al. Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. Clin Infect Dis 2012;55:651–62.10.1093/cid/cis464Suche in Google Scholar

34. Schuetz P, Muller B, Christ-Crain M, Stolz D, Tamm M, Bouadma L, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2012;9:CD007498.10.1002/14651858.CD007498.pub2Suche in Google Scholar

35. Dusemund F, Bucher B, Meyer S, Thomann R, Kuhn F, Bassetti S, et al. Influence of procalcitonin on decision to start antibiotic treatment in patients with a lower respiratory tract infection: insight from the observational multicentric ProREAL surveillance. Eur J Clin Microbiol Infect Dis 2013;32:51–60.10.1007/s10096-012-1713-8Suche in Google Scholar

36. Geiser MM. Procalcitonin Testing in the Puzzle of Sepsis. BioMerieux Report, 2013.Suche in Google Scholar

37. Soni N, Samson D, Galaydick J, Vats V, Huang E, Aronson N, et al. Procalcitonin-guided antibiotic therapy: a systematic review and meta-analysis. J Hosp Med 2013;8:530–40.10.1002/jhm.2067Suche in Google Scholar

38. Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis 2013;13:426–35.10.1016/S1473-3099(12)70323-7Suche in Google Scholar

39. Wu MH, Lin CC, Huang SL, Shih HM, Wang CC, Lee CC, et al. Can procalcitonin tests aid in identifying bacterial infections associated with influenza pneumonia? A systematic review and meta-analysis. Influenza Other Respir Viruses 2013;7:349–55.10.1111/j.1750-2659.2012.00386.xSuche in Google Scholar PubMed PubMed Central

40. Yu CW, Juan LI, Wu MH, Shen CJ, Wu JY, Lee CC. Systematic review and meta-analysis of the diagnostic accuracy of procalcitonin, C-reactive protein and white blood cell count for suspected acute appendicitis. Br J Surg 2013;100:322–9.10.1002/bjs.9008Suche in Google Scholar PubMed

41. Berg P, Lindhardt BO. The role of procalcitonin in adult patients with community-acquired pneumonia–a systematic review. Dan Med J 2012;59:A4357.Suche in Google Scholar

42. Briel M, Christ-Crain M, Young J, Schuetz P, Huber P, Periat P, et al. Procalcitonin-guided antibiotic use versus a standard approach for acute respiratory tract infections in primary care: study protocol for a randomised controlled trial and baseline characteristics of participating general practitioners [ISRCTN73182671]. BMC Fam Pract 2005;6:34.10.1186/1471-2296-6-34Suche in Google Scholar PubMed PubMed Central

43. Briel M, Schuetz P, Mueller B, Young J, Schild U, Nusbaumer C, et al. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med 2008;168:2000–7; discussion 7–8.10.1001/archinte.168.18.2000Suche in Google Scholar PubMed

44. Schuetz P, Albrich W, Christ-Crain M, Chastre J, Mueller B. Procalcitonin for guidance of antibiotic therapy. Expert Rev Anti Infect Ther 2010;8:575–87.10.1586/eri.10.25Suche in Google Scholar PubMed

45. Schuetz P, Chiappa V, Briel M, Greenwald JL. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med 2011;171:1322–31.10.1001/archinternmed.2011.318Suche in Google Scholar PubMed

46. Tang H, Huang T, Jing J, Shen H, Cui W. Effect of procalcitonin-guided treatment in patients with infections: a systematic review and meta-analysis. Infection 2009;37:497–507.10.1007/s15010-009-9034-2Suche in Google Scholar PubMed

47. Wolff M, Bouadma L. What procalcitonin brings to management of sepsis in the ICU. Crit Care 2010;14:1007.10.1186/cc9330Suche in Google Scholar PubMed PubMed Central

48. Agarwal R, Schwartz DN. Procalcitonin to guide duration of antimicrobial therapy in intensive care units: a systematic review. Clin Infect Dis 2011;53:379–87.10.1093/cid/cir408Suche in Google Scholar PubMed

49. Albrich WC, Dusemund F, Bucher B, Meyer S, Thomann R, Kuhn F, et al. Effectiveness and safety of procalcitonin-guided antibiotic therapy in lower respiratory tract infections in “real life”: an international, multicenter poststudy survey (ProREAL). Arch Intern Med 2012;172:715–22.10.1001/archinternmed.2012.770Suche in Google Scholar PubMed

50. Deliberato RO, Marra AR, Sanches PR, Martino MD, Ferreira CE, Pasternak J, et al. Clinical and economic impact of procalcitonin to shorten antimicrobial therapy in septic patients with proven bacterial infection in an intensive care setting. Diagn Micr Infect Dis 2013;76:266–71.10.1016/j.diagmicrobio.2013.03.027Suche in Google Scholar PubMed

51. Heyland DK, Johnson AP, Reynolds SC, Muscedere J. Procalcitonin for reduced antibiotic exposure in the critical care setting: a systematic review and an economic evaluation. Crit Care Med 2011;39:1792–9.10.1097/CCM.0b013e31821201a5Suche in Google Scholar PubMed

52. Schuetz P, Muller B, Christ-Crain M, Stolz D, Tamm M, Bouadma L, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Evid Based Child Health 2013;8:1297–371.10.1002/14651858.CD007498.pub2Suche in Google Scholar PubMed PubMed Central

53. Soni N, Samson D, Galaydick J, Vats V, Pitrak D, Aronson N. Procalcitonin-guided antibiotic therapy. Comparative effectiveness review No. 78. AHRQ Publication No. 12(13)-EHC124-EF. Rockville, MD: Agency for Healthcare Research and Quality: Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center under Contract No. 290-2007-10058-I, 2012.Suche in Google Scholar

54. Chen M, Wang L, Chen W, Zhang L, Jiang H, Mao W. Does economic incentive matter for rational use of medicine? China’s experience from the essential medicines program. PharmacoEconomics 2014;32:245–55.10.1007/s40273-013-0068-zSuche in Google Scholar PubMed

55. Thomson S, Osborn R, Squires D, Reed SJ. International Profiles of Health Care Systems, 2011. The Commonwealth Fund, November 2011.Suche in Google Scholar

56. WHO. Chronic Respiratory Diseases. Geneva, Switzerland: World Health Organization, 2005.Suche in Google Scholar

57. LIU Yue-hua WJ-h, Zhang Jie. Emergency Disease spectrum in China: based on Hospital Database From Beijing. Beijing, China: Tsinghua University, May 2015.10.1016/j.jval.2015.03.509Suche in Google Scholar

58. He R, Luo B, Hu C, Li Y, Niu R. Differences in distribution and drug sensitivity of pathogens in lower respiratory tract infections between general wards and RICU. J Thorac Dis 2014;6:1403–10.Suche in Google Scholar

59. Wang J, Wang Q, Bi Z. [A surveillance on acute respiratory infection]. Zhonghua liu xing bing xue za zhi 1994;15:141–4.Suche in Google Scholar

60. Zhang Y, Yao Z, Zhan S, Yang Z, Wei D, Zhang J, et al. Disease burden of intensive care unit-acquired pneumonia in China: a systematic review and meta-analysis. Intern J Infect Dis 2014;29:84–90.10.1016/j.ijid.2014.05.030Suche in Google Scholar PubMed

61. Cheng A, Ren N, Wen X. A nosocomial infection point-prevalence survey: results and analysis of 193 Hospitals in China in 2001. Chin J Nosocomiol 2002;12:561 – 3.Suche in Google Scholar

62. Fu C, Yang J. Influence of carrying out zero price addition policy of drugs on public hospital expenses in shenzhen. Chinese Hospital Management 2013;33:4–6.Suche in Google Scholar

63. He S, Chen B, Li W, Yan J, Chen L, Wang X, et al. Ventilator-associated pneumonia after cardiac surgery: a meta-analysis and systematic review. J Thorac Cardiovasc Surg 2014;148:3148–55.e1–5.10.1016/j.jtcvs.2014.07.107Suche in Google Scholar PubMed

64. Zhang X, Wang R, Di X, Liu B, Liu Y. Different microbiological and clinical aspects of lower respiratory tract infections between China and European/American countries. J Thorac Dis 2014;6:134–42.Suche in Google Scholar

65. Li Y, Xu J, Wang F, Wang B, Liu L, Hou W, et al. Overprescribing in China, driven by financial incentives, results in very high use of antibiotics, injections, and corticosteroids. Health Aff (Millwood) 2012;31:1075–82.10.1377/hlthaff.2010.0965Suche in Google Scholar PubMed

66. Huang HH, Zhang YY, Xiu QY, Zhou X, Huang SG, Lu Q, et al. Community-acquired pneumonia in Shanghai, China: microbial etiology and implications for empirical therapy in a prospective study of 389 patients. Eur J Clin Microbiol Infect Dis 2006;25:369–74.10.1007/s10096-006-0146-7Suche in Google Scholar PubMed

67. Liu YN, Cao B, Wang H, Chen LA, She DY, Zhao TM, et al. [Adult hospital acquired pneumonia: a multicenter study on microbiology and clinical characteristics of patients from 9 Chinese cities]. Zhonghua jie he he hu xi za zhi 2012;35:739–46.Suche in Google Scholar

68. He LX. [Guidelines for the diagnosis and treatment of community-acquired pneumonia: learning and practicing]. Zhonghua jie he he hu xi za zhi 2006;29:649–50.Suche in Google Scholar

69. Li C, Ren N, Wen X, Zhou P, Huang X, Gong R, et al. Changes in antimicrobial use prevalence in China: results from five point prevalence studies. PLoS One 2013;8:e82785.10.1371/journal.pone.0082785Suche in Google Scholar PubMed PubMed Central

70. Ding JG, Sun QF, Li KC, Zheng MH, Miao XH, Ni W, et al. Retrospective analysis of nosocomial infections in the intensive care unit of a tertiary hospital in China during 2003 and 2007. BMC Infect Dis 2009;9:115.10.1186/1471-2334-9-115Suche in Google Scholar PubMed PubMed Central

71. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532–55.10.1164/rccm.200703-456SOSuche in Google Scholar PubMed

72. Gao J, Prasad N. Chronic obstructive pulmonary disease in China: the potential role of indacaterol. J Thorac Dis 2013;5:549–58.Suche in Google Scholar

73. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl 2):S27–72.10.1086/511159Suche in Google Scholar PubMed PubMed Central

74. Liu Y, Chen M, Zhao T, Wang H, Wang R, Cai B, et al. Causative agent distribution and antibiotic therapy assessment among adult patients with community acquired pneumonia in Chinese urban population. BMC Infect Dis 2009;9:31.10.1186/1471-2334-9-31Suche in Google Scholar PubMed PubMed Central

75. Long W, Deng X, Zhang Y, Lu G, Xie J, Tang J. Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with community-acquired pneumonia. Respirology 2011;16:819–24.10.1111/j.1440-1843.2011.01978.xSuche in Google Scholar PubMed

76. Schuetz P, Briel M, Christ-Crain M, Wolbers M, Stolz D, Tamm M, et al. Procalcitonin to initiate or withhold antibiotics in acute respiratory tract infections (Protocol). Cochrane Database Syst Rev 2008. Art. No.: CD007498.10.1002/14651858.CD007498Suche in Google Scholar

77. Cai BQ, Cai SX, Chen RC, Cui LY, Feng YL, Gu YT, et al. Expert consensus on acute exacerbation of chronic obstructive pulmonary disease in the People’s Republic of China. Int J Chron Obstruct Pulmon Dis 2014;9:381–95.10.2147/COPD.S58454Suche in Google Scholar PubMed PubMed Central

78. Li ZP, Huang JQ, Tang KJ. [Retrospective studies on 713 cases chronic obstructive pulmonary disease]. Zhonghua liu xing bing xue za zhi 2003;24:722–4.Suche in Google Scholar

79. Schuetz P, Balk R, Briel M, Kutz A, Christ-Crain M, Stolz D, et al. Economic evaluation of procalcitonin-guided antibiotic therapy in acute respiratory infections: a US health system perspective. Clin Chem Lab Med 2015;53:583–92.10.1515/cclm-2014-1015Suche in Google Scholar PubMed

80. van Zanten AR, Engelfriet PM, van Dillen K, van Veen M, Nuijten MJ, Polderman KH. Importance of nondrug costs of intravenous antibiotic therapy. Crit Care 2003;7:R184–90.10.1186/cc2388Suche in Google Scholar PubMed PubMed Central

81. Michaelidis CI, Zimmerman RK, Nowalk MP, Fine MJ, Smith KJ. Cost-effectiveness of procalcitonin-guided antibiotic therapy for outpatient management of acute respiratory tract infections in adults. J Gen Intern Med 2014;29:579–86.10.1007/s11606-013-2679-7Suche in Google Scholar PubMed PubMed Central

82. Lee M, Snyder A. The role of procalcitonin in community-acquired pneumonia: a literature review. Adv Emerg Nurs J 2012;34:259–71.10.1097/TME.0b013e318261338dSuche in Google Scholar PubMed

83. Bishop BM, Bon JJ, Trienski TL, Pasquale TR, Martin BR, File TM, Jr. Effect of introducing procalcitonin on antimicrobial therapy duration in patients with sepsis and/or pneumonia in the intensive care unit. Ann Pharmacother 2014;48:577–83.10.1177/1060028014520957Suche in Google Scholar PubMed

84. Cohen B, Larson EL, Stone PW, Neidell M, Glied SA. Factors associated with variation in estimates of the cost of resistant infections. Med Care 2010;48:767–75.10.1097/MLR.0b013e3181e358b9Suche in Google Scholar PubMed PubMed Central

Received: 2016-4-22
Accepted: 2016-8-1
Published Online: 2016-9-22
Published in Print: 2017-3-1

©2017 Walter de Gruyter GmbH, Berlin/Boston

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. The central role of external quality assurance in harmonisation and standardisation for laboratory medicine
  4. Review
  5. Fecal calprotectin in inflammatory bowel diseases: update and perspectives
  6. Mini Review
  7. Factor VIIa-antithrombin complex: a possible new biomarker for activated coagulation
  8. Opinion Papers
  9. Improving quality in the preanalytical phase through innovation, on behalf of the European Federation for Clinical Chemistry and Laboratory Medicine (EFLM) Working Group for Preanalytical Phase (WG-PRE)
  10. Metabolite profiling can change health-care delivery to obese patients with fatty liver disease: the search for biomarkers
  11. Genetics and Molecular Diagnostics
  12. Rapid screening for targeted genetic variants via high-resolution melting curve analysis
  13. Evaluation of the new cobas® HCV genotyping test based on real-time PCRs of three different HCV genome regions
  14. General Clinical Chemistry and Laboratory Medicine
  15. Harmonisation of serum dihydrotestosterone analysis: establishment of an external quality assurance program
  16. Spanish Preanalytical Quality Monitoring Program (SEQC), an overview of 12 years’ experience
  17. Peer groups splitting in Croatian EQA scheme: a trade-off between homogeneity and sample size number
  18. Prevalence of pseudonatremia in a clinical laboratory – role of the water content
  19. Retrospective validation of a β-trace protein interpretation algorithm for the diagnosis of cerebrospinal fluid leakage
  20. Economic evaluation of procalcitonin-guided antibiotic therapy in acute respiratory infections: a Chinese hospital system perspective
  21. Performance evaluation of ImmunoCAP® ISAC 112: a multi-site study
  22. Clinical autoantibody detection by microarray
  23. Cardiovascular Diseases
  24. Kinetics of troponin I in patients with myocardial injury after noncardiac surgery
  25. Infectious Diseases
  26. P35 and P22 Toxoplasma gondii antigens abbreviate regions to diagnose acquired toxoplasmosis during pregnancy: toward single-sample assays
  27. Letters to the Editor
  28. Deciphering a macro-troponin I complex; a case report
  29. Interference of laboratory disinfection with trichloro-isocyanuric acid on cardiac troponin I measurement using the Vitros immunoassay system
  30. Massive interference in free T4 and free T3 assays misleading clinical judgment
  31. In defense of aldosterone measurement by immunoassay: a broader perspective
  32. The prevalence of hemolysis – a survey using hemolysis index
  33. Detection of BRAFV600K mutant tumor-derived DNA in the pleural effusion from a patient with metastatic melanoma
  34. Evaluation of the accuracy of the Greiner Bio-One FC Mix Glucose tube
  35. Congress Abstracts
  36. 4th EFLM-BD European Conference on Preanalytical Phase Amsterdam (NL), 24–25 March 2017
https://doi.org/10.1515/cclm-2016-0349
Schlagwörter für diesen Artikel
antibiotic stewardship; Chinese health system; cost saving; economic evaluation; procalcitonin; respiratory infection

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. The central role of external quality assurance in harmonisation and standardisation for laboratory medicine
  4. Review
  5. Fecal calprotectin in inflammatory bowel diseases: update and perspectives
  6. Mini Review
  7. Factor VIIa-antithrombin complex: a possible new biomarker for activated coagulation
  8. Opinion Papers
  9. Improving quality in the preanalytical phase through innovation, on behalf of the European Federation for Clinical Chemistry and Laboratory Medicine (EFLM) Working Group for Preanalytical Phase (WG-PRE)
  10. Metabolite profiling can change health-care delivery to obese patients with fatty liver disease: the search for biomarkers
  11. Genetics and Molecular Diagnostics
  12. Rapid screening for targeted genetic variants via high-resolution melting curve analysis
  13. Evaluation of the new cobas® HCV genotyping test based on real-time PCRs of three different HCV genome regions
  14. General Clinical Chemistry and Laboratory Medicine
  15. Harmonisation of serum dihydrotestosterone analysis: establishment of an external quality assurance program
  16. Spanish Preanalytical Quality Monitoring Program (SEQC), an overview of 12 years’ experience
  17. Peer groups splitting in Croatian EQA scheme: a trade-off between homogeneity and sample size number
  18. Prevalence of pseudonatremia in a clinical laboratory – role of the water content
  19. Retrospective validation of a β-trace protein interpretation algorithm for the diagnosis of cerebrospinal fluid leakage
  20. Economic evaluation of procalcitonin-guided antibiotic therapy in acute respiratory infections: a Chinese hospital system perspective
  21. Performance evaluation of ImmunoCAP® ISAC 112: a multi-site study
  22. Clinical autoantibody detection by microarray
  23. Cardiovascular Diseases
  24. Kinetics of troponin I in patients with myocardial injury after noncardiac surgery
  25. Infectious Diseases
  26. P35 and P22 Toxoplasma gondii antigens abbreviate regions to diagnose acquired toxoplasmosis during pregnancy: toward single-sample assays
  27. Letters to the Editor
  28. Deciphering a macro-troponin I complex; a case report
  29. Interference of laboratory disinfection with trichloro-isocyanuric acid on cardiac troponin I measurement using the Vitros immunoassay system
  30. Massive interference in free T4 and free T3 assays misleading clinical judgment
  31. In defense of aldosterone measurement by immunoassay: a broader perspective
  32. The prevalence of hemolysis – a survey using hemolysis index
  33. Detection of BRAFV600K mutant tumor-derived DNA in the pleural effusion from a patient with metastatic melanoma
  34. Evaluation of the accuracy of the Greiner Bio-One FC Mix Glucose tube
  35. Congress Abstracts
  36. 4th EFLM-BD European Conference on Preanalytical Phase Amsterdam (NL), 24–25 March 2017
Jetzt anmelden und 20% sparen
Institutioneller Zugang
Wie funktioniert Authentifizierung?
Haben Sie eine Idee, wie wir unsere Website verbessern können?
Bitte schreiben Sie uns.
© 2025 De Gruyter Brill
Heruntergeladen am 27.10.2025 von https://www.degruyterbrill.com/document/doi/10.1515/cclm-2016-0349/html
Button zum nach oben scrollen